Tech Transfer: 9th BioVaria to take place in Munich on 17 May 2016
Ascenion unveils technology highlights: New approaches for the treatment of neurodegenerative disorders and glioblastoma.
On 17 May 2016, dealmakers and investors from the international biopharmaceutical industry will come together in Munich with Europe’s leading life-science researchers, entrepreneurs and technology transfer professionals to initiate partnerships for the development of high-potential academic projects. Ascenion and 12 further technology transfer organisations from across Europe will present a total of 40 peer-selected technologies, including innovative diagnostic and therapeutic approaches, as well as platform technologies, originating from 32 research institutes and universities in 8 European nations. In addition, BioVaria’s Spin-off Panel will feature 8 of Europe’s most promising spin-offs.
Ascenion will present a total of five projects, including an innovative approach for the treatment of neurodegenerative diseases originating from the German Center for Neurodegenerative Diseases (DZNE) and a radioimmunotherapy for the treatment of glioblastoma currently being developed by the Helmholtz Zentrum München in close collaboration with a group of university clinics.
The first project targets the PERK pathway that was shown to be relevant in the development of tauopathies, i.e., neurodegenerative diseases characterised by the pathological aggregation of tau protein (tau tangles) in neurons of the CNS. While most approaches in this field aim to inhibit PERK, the DZNE team is pioneering the strategy of activating it. In relevant in vivo models, this has proved highly promising: an orally given PERK activator led to reduced tau pathology, reduced dendritic spine loss and motor neuron loss, and improved memory and locomotor function.
The second project builds on positive results obtained with an inhibitory anti-CAXII antibody in xenograft tumour models demonstrating its capacity to reduce tumour size and growth. CAXII is an enzyme which is expressed to 100% on glioblastomas but not on healthy brain tissue. Using translational grants, researchers and clinicians are now working together to increase the efficacy of the approach by conjugating a Fab-fragment of the antibody to a radionuclide and advancing the conjugate to clinical stage. A GMP process for the production of CAXII-specific Fabs linked with lutetium-177 is currently under development.
Further BioVaria projects presented by Ascenion are
The proven BioVaria format with its short presentations, all-day poster exhibition and interactive Spin-off Panel provides an unprecedented density of life-science innovations in just one day. At the same time, it allows plenty of opportunity for individual discussions with scientists and their technology transfer representatives.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance